Solid Tumors: Genetic Testing & Biomarkers

If you're focusing on this Category and want to learn from the best, then check out the content we have for you.

Proudly supported by

Book My Place

By submitting you agree to the Terms & Privacy Policy

Meet our Speakers

We've gathered some of the top experts in the field to discuss this topic. With years of experience between them, they're well-equipped to offer invaluable insights and perspectives.

Antonio Facchiano

Antonio Facchiano

Istituto Dermopatico dell’Immacolata (IDI-IRCCS), Rome, Italy

John L. Marshall

John L. Marshall

Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Washington DC, USA

Jianyu Rao

Jianyu Rao

UCLA Medical Center, Santa Monica, LA, USA

Jonathan A. Kelber

Jonathan A. Kelber

Department of Biology, California State University Northridge (CSUN), Los Angeles, California

Iris Car

Iris Car

University of Rijeka, Department of Biotechnology, Rijeka, Croatia

Marzia Del Re

Marzia Del Re

Unit of Clinical Pharmacology and Pharmacogenetics, Azienda Ospedaliero-Universitaria Pisana, Pisa

Zoran Gatalica

Zoran Gatalica

The University of Oklahoma Health Sciences Center, Oklahoma City, USA

Cara Haymaker

Cara Haymaker

Director, (ORION), UT MD Anderson Cancer Center, Houston, TX, US

Francisco La Rosa

Francisco La Rosa

University of Colorado, AMC Department of Pathology, Aurora, CO, US

Jing Li

Jing Li

Universitat Autònoma de Barcelona, Barcelona, Spain

Ye-Lin Liang

Ye-Lin Liang

Sun Yat-sen University Cancer center, Guangzhou, China

Dario Longo

Dario Longo

Institute of Biostructures and Bioimaging (IBB), Italian National Research Council, Torino, Italy

Cristina M. Failla

Cristina M. Failla

Experimental Immunology Laboratory, IDI-IRCCS, Rome, Italy

Y-h. Taguchi

Y-h. Taguchi

Department of Physics, Chuo University, Tokyo, Japan

Talks

Modeling Therapy-Induced Tumor Cell State Plasticity to Identify Vulnerabilities for Reducing Disease Burden

20 September 2021, 12:00 PM
Jonathan A. Kelber

Identification of distinct immune signatures in malignant pleural mesothelioma

20 September 2021, 03:00 PM
Cara Haymaker

Unleashing the potential of liquid biopsy in solid tumors: diagnosis, recurrence and resistance

21 September 2021, 12:00 PM
Marzia Del Re

Proteomic and N-glycome profiling of secretome from BRAFV600E mutant colon cancer cells with acquired resistance to vemurafenib

21 September 2021, 03:00 PM
Iris Car

Investigating protein- and gene-expression of 27 cytokines/chemokines in melanoma patients. Identification of a 4-genes signature

22 September 2021, 09:00 AM
Antonio Facchiano

Molecular Testing and Liquid Biopsy for Ovarian Cancer

22 September 2021, 12:00 PM
Jianyu Rao

Identification of Novel Biomarkers of Response to Irinotecan in Patients with Colorectal Cancer

22 September 2021, 03:00 PM
Jing Li

Vitiligo and vitiligo-associated markers as indicators of response to immunological checkpoint inhibitors in cutaneous melanoma

23 September 2021, 01:00 PM
Cristina M. Failla

Imaging of tumor acidosis for monitoring response to novel anticancer therapies

24 September 2021, 12:00 PM
Dario Longo

Tensor-Decomposition-Based Unsupervised Feature Extraction Applied to Prostate Cancer Multiomics Data

24 September 2021, 01:00 PM
Y-h. Taguchi

The Third Dimension in Prostate Cancer

24 September 2021, 02:00 PM
Francisco La Rosa

Apocrine breast carcinoma from biomarkers to therapy

26 September 2021, 12:00 PM
Zoran Gatalica

The Evolution of Precision Medicine- Entering the Era of Muliti-omics

26 September 2021, 01:00 PM
John L. Marshall

A lncRNA signature associated with tumour immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma

26 September 2021, 02:00 PM
Ye-Lin Liang